COVID-19: An Overview of SARS-CoV-2 Variants—The Current Vaccines and Drug Development

Table 1

SARS-CoV-2 variants of interest (VOI) [49].

SARS-CoV-2 variants nomenclature				First identification	Current status	Date of designation
WHO label	Pango lineages	GISAID clade	Nextstrain clade
Epsilon	B.1.427 and B.1.429	GH/452R.V1	21C	United States of America	VBM	VOI: 5-Mar-2021; Previous VOI: 6-Jul-2021
Zeta	P .2	GR/484K.V2	20B/S.484K	Brazil	VBM	VOI: 17-Mar2021; Previous VOI: 6-Jul-2021
Eta	B.1.525	G/484K.V3	21D	Multiple countries	VBM	VOI: 17-Mar2021; Previous VOI: 20-Sep-2021
Theta	P.3	GR/1092K.V1	21E	Philippines		VOI: 24-Mar2021; Previous VOI: 6-Jul-2021
Iota	B.1.526	GH/253G.V1	21F	United States of America	VBM	VOI: 24-Mar-2021; Previous VOI: 20-Sep-2021
Kappa	B.1.617.1	G/452R.V3	21B	India	VBM	VOI: 4-Aprl-2021; Previous VOI: 20-Sep-2021
Lambda	C.37	GR/452Q.V1	21G	Peru		VOI: 14-Jun-2021; Previous VOI: 9-Mar-2022
Mu	B.1.621	GH	21H	Colombia	VBM	VOI: 30-Aug-2021; Previous VOI: 9-Mar-2022

VOI: variants of interest; VOC: variants of concern; VBM: variant being monitored.